GSK Signed a Multiyear Exclusive Collaborative Agreement with 23andMe to use Genetic Databases to Develop Novel Therapies.
Shots:
- With this collaboration GSK plans improve target selection to develop “Precision Medicine” with better efficacy and safety
- To identify specific subgroups population to develop targeted treatments
- GSK is initially planning to leverage 23andMe databases for the development of its LRRK2i molecule in preclinical stage targeting Parkinson’s
Ref: GSK | Image: GSK
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
